Fibroblastic Reticular Cells – Their Influence on T Cell Environments & Lung Cancer Immunity

The research group of the Institute of Immunobiology focuses on immune defense against infectious agents, tumor immunology, and developmental immunology. Particularly, Lucas Onder and his colleagues investigate the interaction of fibroblastic reticular cells (FRCs) and immune cells during lymphoid organ development and in various diseases, such as cancer.
In doing so, they characterize FRCs. Their findings show that these cells are not only structural components of tissues: they are also active participants in immune responses, especially in the context of non-small cell lung cancer (NSCLC).

Until 20 years ago, the immunological role of fibroblasts was unclear. Early studies indicated that viral infections in mice affected the fibroblastic component of lymphoid organs, thereby impacting the effectiveness of the immune response and suggesting an immunological function of FRCs.
This discovery led to the creation of mouse models targeting FRCs and the creation of genetic tools for FRC-specific manipulation and imaging. Research has increased understanding of FRCs in mice and is now exploring their roles in human lymphoid organs and inflammatory tissues, like lung tumors. Future studies should identify FRC functions and factors for potential use in immunotherapy.
 

Lucas Onder and his colleagues demonstrate that FRCs are important for maintaining the immune system’s balance (homeostasis). Their findings highlight the potential of FRCs as promising target for cancer therapies. As our understanding in immunology evolves, insights from FRC research will be vital for developing effective cancer treatment strategies.

Ongoing research on FRCs relies on the collaboration among various research groups worldwide. FRCs are present in nearly all tissues where immune cells are active, indicating that studying FRCs can instruct many areas of immunological research. The scientific community is just beginning to understand FRC biology in human tissues, both in health and disease. Addressing this challenge requires teamwork among researchers.

New genetic models, innovative imaging techniques, and high-dimensional multi-omics will shape the future of FRC research. Additionally, the field should focus on expanding knowledge about human FRCs, particularly in diseased tissues. By combining genetic studies in model systems with observations in human tissues, researchers can significantly advance their understanding of FRCs.

The Medical Research Center (MFZ) at the Cantonal Hospital of St.Gallen integrates the Clinical Trials Unit (CTU), the Institute of Immunobiology, and clinical research laboratories.
This collaboration creates interfaces between clinical research and basic research, supporting a variety of research projects, including clinical trials and immunological studies. 

• Research initiatives: The Institute of Immunobiology leads innovative research initiatives while maintaining the MFZ's technical infrastructure, including advanced imaging technologies and laboratory facilities
• Comprehensive services: The Clinical Trials Unit offers extensive services to assist clinical researchers in effectively implementing their projects

The Cantonal Hospital of St.Gallen is part of HOCH Health Ostschweiz, a company consisting of five hospitals in Eastern Switzerland. 

LinkedIn profile of Dr. Lucas Onder
LinkedIn profile of HOCH Health Ostschweiz